Scynexis (SCYX) Amortizatization of Intangibles (2016 - 2026)
Scynexis' (SCYX) quarterly Amortizatization of Intangibles came in at $95000.0 in Q2 2026, down 17.39% on a YoY basis from $115000.0 in Q2 2025, and up 4.4% quarter-over-quarter from $91000.0 in Q1 2026.
Powered by 
Analysis
Scynexis (SCYX) Amortizatization of Intangibles (2016 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Amortizatization of Intangibles for 9 consecutive years, with $95000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Amortizatization of Intangibles fell 17.39% year-over-year to $95000.0; the trailing twelve-month figure through Jun 2026 stood at $346000.0 (down 66.51% YoY), and the FY2025 full-year result was $474000.0, down 64.63% from the prior year.
- Amortizatization of Intangibles grew to $95000.0 in Q2 2026 per SCYX's latest filing, from $91000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $638000.0 in Q4 2023 and bottomed at -$109000.0 in Q2 2023.
- Historically, Amortizatization of Intangibles has averaged $202722.2 across 5 years, with a median of $134500.0 in 2022.
- The widest YoY moves for Amortizatization of Intangibles: up 1060.78% in 2023, down 309.62% in 2023.
- Over 5 years, Amortizatization of Intangibles stood at $154000.0 in 2022, then soared by 314.29% to $638000.0 in 2023, then sank by 61.91% to $243000.0 in 2024, then plunged by 74.49% to $62000.0 in 2025, then surged by 53.23% to $95000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $95000.0, $91000.0, and $62000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 1.39 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 95,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 95,000.00 |
| Mar 31, 2026 | 91,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 199,000.00 |
| Dec 31, 2024 | 243,000.00 |
| Sep 30, 2024 | 476,000.00 |
| Jun 30, 2024 | 368,000.00 |
| Mar 31, 2024 | 253,000.00 |
| Dec 31, 2023 | 638,000.00 |
| Sep 30, 2023 | 592,000.00 |
| Jun 30, 2023 | -109,000.00 |
| Mar 31, 2023 | 219,000.00 |
| Dec 31, 2022 | 154,000.00 |
| Sep 30, 2022 | 51,000.00 |
| Jun 30, 2022 | 52,000.00 |
| Mar 31, 2022 | 52,000.00 |
| Dec 31, 2021 | 49,000.00 |
| Sep 30, 2021 | 49,000.00 |